Bravecto (4.5 - 10 kg)
Active substance
ATC code
Species
Dogs
Indications
For the treatment of tick and flea infestations in dogs.
This veterinary medicinal product is a systemic insecticide and acaricide that provides:
- immediate and persistent flea (Ctenocephalides felis) killing activity for 12 weeks,
- immediate and persistent tick killing activity for 12 weeks for Ixodes ricinus, Dermacentor reticulatus and D. variabilis,
- immediate and persistent tick killing activity for 8 weeks for Rhipicephalus sanguineus,
- persistent tick killing activity from 7 days to 12 weeks after treatment for Ixodes hexagonus.
Fleas and ticks must attach to the host and commence feeding in order to be exposed to the active substance.
The product can be used as part of a treatment strategy for the control of flea allergy dermatitis (FAD).
For the treatment of demodicosis caused by Demodex canis.
For the treatment of sarcoptic mange (Sarcoptes scabiei var. canis) infestation.
For reduction of the risk of infection with Babesia canis canis via transmission by Dermacentor reticulatus for up to 12 weeks. The effect is indirect due to the product’s activity against the vector.
For reduction of the risk of infection with Dipylidium caninum via transmission by Ctenocephalides felis for up to 12 weeks. The effect is indirect due to the product’s activity against the vector.
Dose to be administered and administration route
For oral use.
Bravecto should be administered in accordance with the following table (corresponding to a dose of 25 – 56 mg fluralaner/kg bodyweight within one weight band):
|
Bodyweight of dog (kg) |
Strength and number of tablets to be administered |
||||
|
Bravecto 112.5 mg |
Bravecto 250 mg |
Bravecto 500 mg |
Bravecto 1,000 mg |
Bravecto 1,400 mg |
|
|
2 – 4.5 |
1 |
||||
|
>4.5 – 10 |
1 |
||||
|
>10 – 20 |
1 |
||||
|
>20 – 40 |
1 |
||||
|
>40 – 56 |
1 |
||||
The chewable tablets should not be broken or divided.
For dogs above 56 kg body weight, use a combination of two tablets that most closely matches the bodyweight.
Method of administration
Administer Bravecto chewable tablets at or around the time of feeding.
Bravecto is a chewable tablet and is well accepted by most dogs. If the tablet is not taken up voluntarily by the dog it can also be given with food or directly into the mouth. The dog should be observed during administration to confirm that the tablet is swallowed.
Treatment schedule
For optimal control of flea infestation, the veterinary medicinal product should be administered at intervals of 12 weeks. For optimal control of tick infestation, the timing of retreatment depends on the tick species. See section 4.2.
For the treatment of Demodex canis mite infestations, a single dose of the product should be administered. As demodicosis is a multi-factorial disease, it is advisable to also treat any underlying disease appropriately.
For the treatment of sarcoptic mange infestations (Sarcoptes scabiei var. canis), a single dose of the product should be administered. The need for and frequency of retreatment should be in accordance with the advice of the prescribing veterinarian.
Adverse reactions
Mild and transient gastrointestinal effects such as diarrhoea, vomiting, inappetence, and drooling were commonly observed in clinical trials (1.6% of treated dogs).
Lethargy, muscle tremor, ataxia and convulsions have been reported very rarely in spontaneous reports.
Most reported adverse reactions were self-limiting and of short duration.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
